

---

## Product Data Sheet

---

Product Name: GSK3368715

Cat. No.: GC36191

### Chemical Properties

Cas. No. 1629013-22-4

SMILES CNCCN(CC1=CN=C1C2CCC(COCC)(COCC)CC2)CFormula  $C_{20}H_{38}N_4O_2$  M.Wt 366.54Solubility Soluble in DMSO Storage Store at  $-20^{\circ}C$ 

General tips For obtaining a higher solubility, please warm the tube at  $37^{\circ}C$  and shake it in the ultrasonic bath for a while. Stock solution can be stored below  $-20^{\circ}C$  for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure 

### Background

GSK3368715 is an inhibitor of type I protein arginine methyltransferases (PRMTs;  $IC_{50}$ s = 3.1, 162, 38, 4.7, and 39 nM for PRMT1, 3, 4, 6, and 8, respectively).<sup>1</sup> It is selective for type I PRMTs over PRMT5, 7, and 9 ( $IC_{50}$ s = >20,408, >40,000, and >15,000 nM, respectively), as well as 20 additional methyltransferases and a panel of ion channels, receptors, and transporters at 10  $\mu$ M. GSK3368715 (5  $\mu$ M) inhibits the growth of patient-derived diffuse large B cell lymphoma (DLBCL) cells. *In vivo*, GSK3368715 (9.375-150 mg/kg) reduces tumor volume in Toledo DLBCL and BxPC-3 pancreatic adenocarcinoma mouse xenograft models. It also reduces tumor growth in ACHN renal carcinoma and MDA-MB-468 breast cancer mouse xenograft models and a pancreatic adenocarcinoma patient-derived xenograft (PDX) mouse model when administered at doses of 150 and 300 mg/kg, respectively.

1. Fedoriw, A., Rajapurkar, S.R., O'Brien, S., et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. *Cancer Cell* 36(1):100-114.e125 (2019)

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA